Company Encyclopedia
View More
name
Tourmaline Bio
TRML.US
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company’s development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED).
1.902 T
TRML.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Tourmaline Bio Inc. Files Initial Beneficial Ownership Statement Naming Novartis AG

    Tourmaline Bio Inc. has filed an initial beneficial ownership statement, identifying Novartis AG as the beneficial owner. The filing is accessible via EDGAR, the SEC's system. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice.

    Reuters·
    DE
    NOT
    0.00%
    US
    TRML
    0.00%
    Reuters·
    DE
    NOT
    0.00%
    US
    TRML
    0.00%

    Novartis Closes Acquisition of US Biopharmaceutical Group Tourmaline Bio

    Novartis Closes Acquisition of US Biopharmaceutical Group Tourmaline Bio

    marketscreener·
    US
    TRML
    0.00%
    US
    NVS
    +0.16%
    marketscreener·
    US
    TRML
    0.00%
    US
    NVS
    +0.16%

    Tourmaline Bio to Delist from Nasdaq and Deregister

    Tourmaline Bio (TRML) announced its delisting from Nasdaq and deregistration with the SEC after terminating its $100 million ATM Sales Agreement. The company has experienced significant leadership changes post-merger, reflecting a strategic shift. Analysts rate TRML stock as Hold with a $48 price target, while Spark's AI Analyst gives it a Neutral rating, citing financial challenges despite a strong equity position. The current market cap is $1.23 billion, with an average trading volume of 925,808 shares.

    Tip Ranks·
    US
    TRML
    0.00%
    Tip Ranks·
    US
    TRML
    0.00%

    Tourmaline Bio Announces Board and Executive Resignations Following Merger

    Tourmaline Bio, Inc. announced the resignation of several board members and executives on October 28, 2025, following a merger. The resignations were part of the merger agreement and not due to disagreements. Key resignations include the CEO, CFO, and other board members, effective the same date. Replacement information was not disclosed.

    TradingView·
    US
    TRML
    0.00%
    TradingView·
    US
    TRML
    0.00%

    Tourmaline Bio Inc. Completes Merger and Terminates $100 Million ATM Sales Agreement

    Tourmaline Bio Inc. has completed a merger, resulting in the cancellation of outstanding shares into the right to receive merger consideration. The company also terminated its $100 million ATM Sales Agreement with Leerink Partners LLC, contingent upon the merger's completion. This news is for informational purposes only and should not be considered financial or legal advice.

    Reuters·
    US
    TRML
    0.00%
    Reuters·
    US
    TRML
    0.00%
    © 2025 Longbridge｜Disclaimer